Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimmo Porkka

Showing results (51-60 of 142) with videos related to

Pageof 15
Sort By:
Hemasphere|March 2, 2022
Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic LeukemiaHelena Hohtari, Matti Kankainen, Shady Adnan-Awad, et al.
Haematologica|July 18, 2009
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinibThomas Ernst, Franz X Gruber, Oliver Pelz-Ackermann, et al.
Hemasphere|August 15, 2022
How a Medical Association Can Make a Difference in a Crisis SituationNathalie van Havre, Enrica Orsini, Antonio Almeida, et al.
Medical Oncology (Northwood, London, England)|January 12, 2011
BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?Franz X Gruber, Tuija Lundán, Rasmus Goll, et al.
Blood|March 24, 2012
The EUTOS CML score aims to support clinical decision-makingVerena Hoffmann, Michele Baccarani, Joerg Hasford, et al.
Leukemia|June 22, 2018
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CMLOscar Brück, Sami Blom, Olli Dufva, et al.
Leukemia & Lymphoma|March 3, 2021
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation studyJoaquín Martínez-López, Satu Mustjoki, Kimmo Porkka, et al.
Leukemia|December 21, 2018
Dasatinib and navitoclax act synergistically to target NUP98-NSD1<sup>+</sup>/FLT3-ITD<sup>+</sup> acute myeloid leukemiaJarno L Kivioja, Angeliki Thanasopoulou, Ashwini Kumar, et al.
Investigational New Drugs|March 4, 2020
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelomaEric K Rowinsky, Agne Paner, Jesus G Berdeja, et al.
Blood|May 4, 2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Michele Baccarani, Verena Hoffmann, et al.
Pageof 15

Showing results (51-60 of 142) with videos related to

Sort By:
Pageof 15
Hemasphere|March 2, 2022
Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic LeukemiaHelena Hohtari, Matti Kankainen, Shady Adnan-Awad, et al.
Haematologica|July 18, 2009
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinibThomas Ernst, Franz X Gruber, Oliver Pelz-Ackermann, et al.
Hemasphere|August 15, 2022
How a Medical Association Can Make a Difference in a Crisis SituationNathalie van Havre, Enrica Orsini, Antonio Almeida, et al.
Medical Oncology (Northwood, London, England)|January 12, 2011
BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?Franz X Gruber, Tuija Lundán, Rasmus Goll, et al.
Blood|March 24, 2012
The EUTOS CML score aims to support clinical decision-makingVerena Hoffmann, Michele Baccarani, Joerg Hasford, et al.
Leukemia|June 22, 2018
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CMLOscar Brück, Sami Blom, Olli Dufva, et al.
Leukemia & Lymphoma|March 3, 2021
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation studyJoaquín Martínez-López, Satu Mustjoki, Kimmo Porkka, et al.
Leukemia|December 21, 2018
Dasatinib and navitoclax act synergistically to target NUP98-NSD1<sup>+</sup>/FLT3-ITD<sup>+</sup> acute myeloid leukemiaJarno L Kivioja, Angeliki Thanasopoulou, Ashwini Kumar, et al.
Investigational New Drugs|March 4, 2020
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelomaEric K Rowinsky, Agne Paner, Jesus G Berdeja, et al.
Blood|May 4, 2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Michele Baccarani, Verena Hoffmann, et al.
Pageof 15